271 related articles for article (PubMed ID: 25908577)
1. A history of drug development in four acts.
Kinch MS; Hoyer D
Drug Discov Today; 2015 Oct; 20(10):1163-8. PubMed ID: 25908577
[No Abstract] [Full Text] [Related]
2. Drug development and FDA approval, 1938-2013.
Darrow JJ; Kesselheim AS
N Engl J Med; 2014 Jun; 370(26):e39. PubMed ID: 24963591
[No Abstract] [Full Text] [Related]
3. Sure cure: public policy on drug efficacy before 1962.
Swann JP
Publ Am Inst Hist Pharm; 1997; 16():223-61. PubMed ID: 11619897
[No Abstract] [Full Text] [Related]
4. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
5. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
6. Incentives for drug development--the curious case of colchicine.
Kesselheim AS; Solomon DH
N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164
[No Abstract] [Full Text] [Related]
7. Promoting safe and effective drugs for 100 years.
Meadows M
FDA Consum; 2006; 40(1):14-20. PubMed ID: 16528822
[No Abstract] [Full Text] [Related]
8. The cosmetic/drug dilemma: FDA regulation of alpha-hydroxy acids.
Heymann LA
Food Drug Law J; 1997; 52(4):357-75. PubMed ID: 10346670
[No Abstract] [Full Text] [Related]
9. Food and Drug Administration: 100 years of protection.
Mosocco DJ
Home Healthc Nurse; 2007 Mar; 25(3):148-50. PubMed ID: 17353704
[No Abstract] [Full Text] [Related]
10. Fifty Years of Expert Advice - Pharmaceutical Regulation and the Legacy of the Drug Efficacy Study.
Schwartz JL
N Engl J Med; 2016 Nov; 375(21):2015-2017. PubMed ID: 27959733
[No Abstract] [Full Text] [Related]
11. Drug development history, "overview," and what are GCPs?
Heilman RD
Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
[TBL] [Abstract][Full Text] [Related]
12. Using market-exclusivity incentives to promote pharmaceutical innovation.
Kesselheim AS
N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
[No Abstract] [Full Text] [Related]
13. Pediatric regulatory initiatives.
Hirschfeld S; Saint-Raymond A
Handb Exp Pharmacol; 2011; 205():245-68. PubMed ID: 21882115
[TBL] [Abstract][Full Text] [Related]
14. Scientific and legal viability of follow-on protein drugs.
Dudzinski DM; Kesselheim AS
N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608
[No Abstract] [Full Text] [Related]
15. Frances Oldham Kelsey. FDA medical reviewer leaves her mark on history.
Bren L
FDA Consum; 2001; 35(2):24-9. PubMed ID: 11444245
[No Abstract] [Full Text] [Related]
16. A long and winding road; evolution of antimicrobial drug development - crisis management.
Echols RM
Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1311-9. PubMed ID: 23241188
[TBL] [Abstract][Full Text] [Related]
17. Teaching clinicians about drugs--50 years later, whose job is it?
Avorn J
N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
[No Abstract] [Full Text] [Related]
18. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
19. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
Dudzinski DM
Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
[No Abstract] [Full Text] [Related]
20. Assessing the Gold Standard--Lessons from the History of RCTs.
Bothwell LE; Greene JA; Podolsky SH; Jones DS
N Engl J Med; 2016 Jun; 374(22):2175-81. PubMed ID: 27248626
[No Abstract] [Full Text] [Related]
[Next] [New Search]
